EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management

Ralf Weiskirchen

Livers · 06.11.2026 · 6 (6) · 116

DOI: 10.3390/livers6060116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Livers, online erschienen am 06.11.2026. Verfasst von Ralf Weiskirchen. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The publication of the joint EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy represents a watershed moment in hepatology [...]

Zitieren

APA

Weiskirchen, R. (2026). From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management. Livers, 6(6), 116. https://doi.org/10.3390/livers6060116

Vancouver

Weiskirchen R. From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management. Livers. 2026;6(6):116. doi:10.3390/livers6060116

BibTeX
@article{Weiskirchen2026,
  author = {Weiskirchen, Ralf},
  title = {From Therapeutic Nihilism to Precision Hepatology: Resmetirom and Semaglutide as Catalysts for a New Era in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Management},
  journal = {Livers},
  year = {2026},
  volume = {6},
  number = {6},
  pages = {116},
  doi = {10.3390/livers6060116}
}
Kostenlos starten →